Summary Section Content 1Our practice extends from bench top to board room. We advise entrepreneurs and those involved in the transfer of technology relevant to the commercialization of life sciences technologies. Our clients include venture capital, private equity and investment banks investing in the life sciences sector. We advise drug manufacturers, medical device companies, and manufacturers of natural health products, both domestic and international. Our clients also include entities involved in the distribution of health products. In addition, we also have a growing practice representing entities involved in the commercialization of environmental and agricultural applications of the life sciences, including those involved in bio-fuels and bio-products. Our team includes many individuals who hold PhDs or Master's degrees in disciplines relevant to life sciences. As a result, we bring to any mandate an in-depth understanding of the science and technology on which your business is built. A number of our team have held relevant industry related positions, which help us to provide practical advice that is often grounded in a working knowledge of the segment of the sector in which your business operates. Our work with clients and industry associations has positioned us as leaders in the Canadian life sciences regulatory community, helping clients navigate the complex environment of Canadian federal and provincial regulations. We understand the public policy process. As a result, we have the ability to provide strategic and effective advice for regulatory matters. At the same time, our public policy experience makes us a logical choice for those seeking to advocate for the development and implementation of new legislation and regulations involving the life sciences sector. In addition, many of the members of the team are actively involved in the life sciences community, both locally, regionally and nationally. We have worked with leading industry participants to create or support industry associations where members can come together, share knowledge and gain valuable insights. These industry contacts can be helpful to our clients, especially our international clients who are entering the Canadian market. Publications Section Content 2 Life Sciences Brochures (PDF, 1.96 MB) BLG Publications, Articles and BulletinsChantal Saunders and Beverly Moore, "Court Guidance Needed Under Sound Prediction Doctrine," Canada and USA Drug Development & Outsourcing Guide, 2015.Jeffrey Graham, "Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)," Canada and USA Drug Development & Outsourcing Guide, 2015.Mark Vickers and Jennifer Raoul, "Navigating the Patent Prosecution Highway in Canada", Life Sciences Canada, 2014.Robert Eeuwes, “Energy Storage for Renewables Being Written into Ontario Policy”, Renewable Energy & Clean Tech Canada, 2014.Bernadette Corpuz, “New Procurement Regime Under Development in Ontario for Large Renewable Energy Projects”, Renewable Energy & Clean Tech Canada, 2014.Beverley Moore and Chantal Saunders, “Sound Prediction in Canada – The Promise is still Important”, Canada and USA Drug Development & Outsourcing Guide, 2014.Jeffrey Graham, “Canada Moves to Update Drug and Device Legislation”, Canada and USA Drug Development & Outsourcing Guide, 2014 and Biotechnology & CleanTech Canada Guide, 2014. Commercialisation of Health Care: Jurisdictional Comparisons (1st Edition; Publisher — European Lawyer) Life Sciences & Chemical Patent Practice in Canada: A Practical Guide (3rd Edition; Publisher – BLG) Canadian Food & Drug Legislation and Commentary (Editors; Publisher – Lexis Nexis) Canadian Health Law Practice Manual (Authors of Chapter 10: Regulation of Pharmaceuticals; Publisher – Lexis Nexis) BLG Intellectual Property Weekly Abstracts BulletinBeverley Moore and Chantal Saunders, "Supreme Court Issues Decision Discussing Test for Sufficiency of Disclosure in a Patent," Canadian Biotechnology Industry Guide Canada and Canada & US Drug Development Industry Guide, 2013.Christine Collard and David Wood, "Patenting Cleantech: Patent Risks from Disclosures to Third Parties," Renewable Energy & CleanTech Canada, 2013.Brad Pierce, "Accessing Venture Capital for Clean-Tech Ventures," Renewable Energy & CleanTech Canada, 2013. BLG Life Sciences Advisory Bulletins "Canadian Patent Appeal Board Upholds Claims to Non-exemplified Humanized Antibodies", August 2016"Life Sciences Legal Trends in Canada", June 2016 Rankings & Recognition Section Content 3Our group or its members are recognized in: The 2015 Who's Who Legal: CanadaThe 2015 Who's Who Legal: The International Who's Who of Business Lawyers, edition 2015 Representative Work Section Content 4Intellectual property protection, including preparing and prosecuting patent and trademark applications, obtaining patents and trademarks, copyright protection, and preparing, prosecuting and obtaining plant breeders’ rights. Drafting and negotiating licensing, clinical trial, product development, and manufacturing and supply agreements. Advising on regulatory requirements of Canadian federal and provincial agencies including Health Canada, the Canadian Food Inspection Agency and provincial ministries of health. Venture capital, institutional investment and public market financing transactions, acting on behalf of investors, agents or the investee companies. Private and public merger and other acquisitions including due diligence. Intellectual property portfolios and management, including advising on Health Canada Patent Register Application of the NOC regulations and data protection system. Dealings with the Patented Medicine Prices Review Board including undertakings and administrative proceedings before the Board. Public policy including advice on government relations, regulatory affairs and strategic communications.